Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future
Open Access
- 7 February 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 95
Abstract
Ocular diseases cause visual impairment and blindness, imposing a devastating impact on quality of life and a substantial societal economic burden. Many such diseases lack universally effective pharmacotherapies. Therefore, understanding the mediators involved in their pathophysiology is necessary for the development of therapeutic strategies. To this end, the hydrolase activity of soluble epoxide hydrolase (sEH) has been explored in the context of several eye diseases, due to its implications in vascular diseases through metabolism of bioactive epoxygenated fatty acids. In this mini-review, we discuss the mounting evidence associating sEH with ocular diseases and its therapeutic value as a target. Substantial data link sEH with the retinal and choroidal neovascularization underlying diseases such as wet age-related macular degeneration, retinopathy of prematurity, and proliferative diabetic retinopathy, although some conflicting results pose challenges for the synthesis of a common mechanism. sEH also shows therapeutic relevance in non-proliferative diabetic retinopathy and diabetic keratopathy, and sEH inhibition has been tested in a uveitis model. Various approaches have been implemented to assess sEH function in the eye, including expression analyses, genetic manipulation, pharmacological targeting of sEH, and modulation of certain lipid metabolites that are upstream and downstream of sEH. On balance, sEH inhibition shows considerable promise for treating multiple eye diseases. The possibility of local delivery of inhibitors makes the eye an appealing target for future sEH drug development initiatives.Keywords
Funding Information
- National Eye Institute
- National Center for Advancing Translational Sciences
- Retina Research Foundation
- International Retinal Research Foundation
- BrightFocus Foundation
- Carl Marshall and Mildred Almen Reeves Foundation
This publication has 72 references indexed in Scilit:
- Epoxyeicosanoids promote organ and tissue regenerationProceedings of the National Academy of Sciences, 2013
- Choroid Sprouting Assay: An Ex Vivo Model of Microvascular AngiogenesisPLOS ONE, 2013
- Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in miceJournal of Clinical Investigation, 2012
- Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic IndicationsJournal of Medicinal Chemistry, 2011
- Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipidsJournal of Lipid Research, 2010
- 1-Aryl-3-(1-acylpiperidin-4-yl)urea Inhibitors of Human and Murine Soluble Epoxide Hydrolase: Structure−Activity Relationships, Pharmacokinetics, and Reduction of Inflammatory PainJournal of Medicinal Chemistry, 2010
- Short Communication: PPARγ Mediates a Direct Antiangiogenic Effect of ω3-PUFAs in Proliferative RetinopathyCirculation Research, 2010
- Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathwaysProceedings of the National Academy of Sciences, 2008
- Orally Bioavailable Potent Soluble Epoxide Hydrolase InhibitorsJournal of Medicinal Chemistry, 2007
- Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesionsBritish Journal of Ophthalmology, 2007